Adaptive Biotechnologies, a Seattle-based life science company, has revealed a new Lyme disease test that has the ability to detect the disease in its early stages by assessing the response of T immune cells.
According to a recent study, Adaptive’s T-Detect Lyme was proven to be more sensitive than standard testing. T-Detect discovered almost 50 percent of instances, whereas routine testing caught just 30 percent.
This is the second T cell-based test developed by Adaptive. The company is also working on another generation of T cell-based tests for inflammatory bowel disease, multiple sclerosis, and other illnesses.
The post Adaptive Biotechnologies Launches T Cell-based Test for Lyme Disease appeared first on Life Science Washington.